Short Interest in Biodesix, Inc. (NASDAQ:BDSX) Decreases By 7.4%

Biodesix, Inc. (NASDAQ:BDSX) was the recipient of a significant decline in short interest in the month of January. As of January 15th, there was short interest totalling 836,600 shares, a decline of 7.4% from the December 31st total of 903,100 shares. Based on an average daily trading volume, of 420,900 shares, the days-to-cover ratio is currently 2.0 days.

Biodesix Price Performance

Shares of NASDAQ BDSX traded down $0.02 during midday trading on Monday, hitting $1.01. 193,655 shares of the company’s stock were exchanged, compared to its average volume of 476,998. The business’s fifty day moving average price is $1.31 and its two-hundred day moving average price is $1.53. The company has a market cap of $146.92 million, a price-to-earnings ratio of -2.59 and a beta of 1.06. The company has a current ratio of 3.40, a quick ratio of 3.40 and a debt-to-equity ratio of 1.30. Biodesix has a 12-month low of $0.86 and a 12-month high of $2.21.

Biodesix (NASDAQ:BDSX) last issued its quarterly earnings results on Friday, November 1st. The company reported ($0.07) EPS for the quarter, hitting analysts’ consensus estimates of ($0.07). The firm had revenue of $18.15 million for the quarter, compared to analyst estimates of $18.45 million. Biodesix had a negative net margin of 66.84% and a negative return on equity of 275.79%. During the same quarter in the prior year, the firm earned ($0.12) EPS. As a group, research analysts forecast that Biodesix will post -0.35 EPS for the current fiscal year.

Insider Buying and Selling at Biodesix

In other Biodesix news, Director Matthew Strobeck bought 40,000 shares of the stock in a transaction on Tuesday, November 5th. The shares were acquired at an average price of $1.40 per share, with a total value of $56,000.00. Following the acquisition, the director now directly owns 2,606,879 shares of the company’s stock, valued at $3,649,630.60. The trade was a 1.56 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jack W. Schuler purchased 200,000 shares of the business’s stock in a transaction dated Wednesday, November 20th. The stock was bought at an average cost of $1.17 per share, with a total value of $234,000.00. Following the completion of the acquisition, the director now directly owns 31,094,935 shares of the company’s stock, valued at approximately $36,381,073.95. This trade represents a 0.65 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought a total of 315,000 shares of company stock worth $393,500 over the last ninety days. 69.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Biodesix

Institutional investors and hedge funds have recently bought and sold shares of the stock. Stephens Inc. AR bought a new stake in Biodesix during the 4th quarter valued at $303,000. Wilmington Savings Fund Society FSB bought a new position in shares of Biodesix during the third quarter valued at about $10,849,000. Barclays PLC boosted its holdings in shares of Biodesix by 1,140.5% during the third quarter. Barclays PLC now owns 23,036 shares of the company’s stock worth $41,000 after purchasing an additional 21,179 shares during the period. Geode Capital Management LLC grew its stake in shares of Biodesix by 50.7% in the third quarter. Geode Capital Management LLC now owns 804,576 shares of the company’s stock worth $1,433,000 after purchasing an additional 270,724 shares during the last quarter. Finally, Landscape Capital Management L.L.C. purchased a new position in Biodesix during the 3rd quarter valued at about $262,000. 20.96% of the stock is currently owned by institutional investors.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.